N Esteve-Pérez1,2, A Ferrer-Robles3,4, G Gómez-Romero3,4, D Fabián-Gonzalez3,4, M Verd-Rodriguez3,4, L C Mora-Fernandez3,4, J J Segura-Sampedro4,5, S Tejada-Gavela6, R Morales-Soriano4,5. 1. Department of Anesthesiology, University Hospital Son Espases, Ctra. Valldemosa 79, 07010, Palma, Spain. neus.esteve@ssib.es. 2. Malignant Peritoneal Disease Research Group, Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain. neus.esteve@ssib.es. 3. Department of Anesthesiology, University Hospital Son Espases, Ctra. Valldemosa 79, 07010, Palma, Spain. 4. Malignant Peritoneal Disease Research Group, Health Research Institute of the Balearic Islands (IdISBa), Palma, Spain. 5. Peritoneal Surgical Oncology Unit, Department of General and Digestive Surgery, University Hospital Son Espases, Palma, Spain. 6. Laboratory of Neurophysiology, Department of Biology, University of the Balearic Islands, Palma, Spain.
Abstract
BACKGROUND: Cytoreductive surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in peritoneal carcinomatosis treatment causes significant hemodynamic, metabolic, and hematological alterations. Studies on the anesthetic intraoperative management are heterogeneous and scarce. There is a great heterogeneity in the anesthetic management of CRS and HIPEC. The aim of this study is to analyze perioperative hemodynamic goal-directed management and to evaluate the complications arisen until the seventh postoperative day. METHODS: Prospective, observational study of all CRS and HIPEC patients from March 2014 to May 2017. Hemodynamic and clinical parameters were registered during surgery and the first 3 postoperative days. We correlated intraoperative data with the postoperative course until the seventh day. RESULTS: A total of 92 patients were included in the study (age 58.5 ± 10.9 years, 47% colorectal carcinoma, and 38% ovarian carcinoma). Peritoneal Carcinomatosis Index (PCI) (median and ranges) was 10 [0-39]. Cardiac Index (CI) 3.15 l/min-1/m-2 [1.79-5.60]) and Systolic Volume Variation (SVV) (10% [3%-17%]) remained within the values of normality in all surgery phases. A large difference was observed between the minimum and maximum ranges of fluid therapy administered (median 9.8 ml/kg/h [5.3-24.3]), showing a great interindividual variation in the fluids requirement. A direct relationship was observed between PCI and surgery duration, fluid therapy, and intraoperative transfusion percentage (p < 0.02). CONCLUSIONS: There is a great variability in the intraoperative fluid therapy needs of the patients. SVV monitoring makes it possible to adjust the fluid therapy needs in each surgery phase. The use of a hemodynamic goal-directed anesthetic protocol in CRS and HIPEC enables to individually adjust the fluid therapy, avoiding over-hydration and ensuring hemodynamic stability in all surgery phases.
BACKGROUND: Cytoreductive surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in peritoneal carcinomatosis treatment causes significant hemodynamic, metabolic, and hematological alterations. Studies on the anesthetic intraoperative management are heterogeneous and scarce. There is a great heterogeneity in the anesthetic management of CRS and HIPEC. The aim of this study is to analyze perioperative hemodynamic goal-directed management and to evaluate the complications arisen until the seventh postoperative day. METHODS: Prospective, observational study of all CRS and HIPEC patients from March 2014 to May 2017. Hemodynamic and clinical parameters were registered during surgery and the first 3 postoperative days. We correlated intraoperative data with the postoperative course until the seventh day. RESULTS: A total of 92 patients were included in the study (age 58.5 ± 10.9 years, 47% colorectal carcinoma, and 38% ovarian carcinoma). Peritoneal Carcinomatosis Index (PCI) (median and ranges) was 10 [0-39]. Cardiac Index (CI) 3.15 l/min-1/m-2 [1.79-5.60]) and Systolic Volume Variation (SVV) (10% [3%-17%]) remained within the values of normality in all surgery phases. A large difference was observed between the minimum and maximum ranges of fluid therapy administered (median 9.8 ml/kg/h [5.3-24.3]), showing a great interindividual variation in the fluids requirement. A direct relationship was observed between PCI and surgery duration, fluid therapy, and intraoperative transfusion percentage (p < 0.02). CONCLUSIONS: There is a great variability in the intraoperative fluid therapy needs of the patients. SVV monitoring makes it possible to adjust the fluid therapy needs in each surgery phase. The use of a hemodynamic goal-directed anesthetic protocol in CRS and HIPEC enables to individually adjust the fluid therapy, avoiding over-hydration and ensuring hemodynamic stability in all surgery phases.
Authors: Andrea Craus-Miguel; Juan José Segura-Sampedro; Xavier González-Argenté; Rafael Morales-Soriano Journal: Ann Surg Oncol Date: 2021-01-06 Impact factor: 5.344
Authors: June S Peng; Jessica LaPiano; Katy Wang; Kristopher Attwood; Joseph J Skitzki; John M Kane; Valerie A Francescutti Journal: Ann Surg Oncol Date: 2021-08-12 Impact factor: 5.344